EU Regulator Backs Regeneron-Roche's COVID-19 Drug

by Vandana Singh, Benzinga Editor

November 11, 2021 2:03 PM | 1 min read | Make a Comment

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's REGN REGEN-COV.
The casirivimab and imdevimab antibody cocktail (Ronapreve) was backed by the CHMP for treating adults and children over 12 with COVID-19 who do not require oxygen support and are at high risk of severe disease.
Related Link: Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose.
Regeneron is collaborating with Roche Holdings AG RHHBY, primarily responsible for development and distribution outside the U.S.
Price Action: REGN shares are up 0.77% at $627, RHHBY stock is up 0.18% at $50.32 during the market session on the last check Thursday.